These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
261 related articles for article (PubMed ID: 27822406)
1. PD-1 inhibition and treatment of advanced melanoma-role of pembrolizumab. Jazirehi AR; Lim A; Dinh T Am J Cancer Res; 2016; 6(10):2117-2128. PubMed ID: 27822406 [TBL] [Abstract][Full Text] [Related]
2. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Mahoney KM; Freeman GJ; McDermott DF Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918 [TBL] [Abstract][Full Text] [Related]
3. [Development of immune checkpoint inhibitors]. Kitano S Rinsho Ketsueki; 2017; 58(8):966-976. PubMed ID: 28883282 [TBL] [Abstract][Full Text] [Related]
7. [Recent Development of Therapies for Melanoma Using Immune Checkpoint Blockades]. Okuyama R Gan To Kagaku Ryoho; 2016 Jun; 43(6):661-5. PubMed ID: 27306802 [TBL] [Abstract][Full Text] [Related]
8. Checkpoint immunotherapy by nivolumab for treatment of metastatic melanoma. Koppolu V; Rekha Vasigala VK J Cancer Res Ther; 2018; 14(6):1167-1175. PubMed ID: 30488824 [TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint inhibitors for nonsmall cell lung cancer treatment. Chen YM J Chin Med Assoc; 2017 Jan; 80(1):7-14. PubMed ID: 27693088 [TBL] [Abstract][Full Text] [Related]
10. Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents. Weber JS; Postow M; Lao CD; Schadendorf D Oncologist; 2016 Oct; 21(10):1230-1240. PubMed ID: 27401894 [TBL] [Abstract][Full Text] [Related]
11. The Era of Checkpoint Inhibition: Lessons Learned from Melanoma. Paschen A; Schadendorf D Recent Results Cancer Res; 2020; 214():169-187. PubMed ID: 31473853 [TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint blocker-related sarcoid-like granulomatous inflammation: a rare adverse event detected in lymph node aspiration cytology of patients treated for advanced malignant melanoma. Rodriguez EF; Lipson E; Suresh K; Cappelli LC; Monaco SE; Maleki Z Hum Pathol; 2019 Sep; 91():69-76. PubMed ID: 31279873 [TBL] [Abstract][Full Text] [Related]
13. Short-term CTLA-4 blockade directly followed by PD-1 blockade in advanced melanoma patients: a single-center experience. Meerveld-Eggink A; Rozeman EA; Lalezari F; van Thienen JV; Haanen JBAG; Blank CU Ann Oncol; 2017 Apr; 28(4):862-867. PubMed ID: 28158487 [TBL] [Abstract][Full Text] [Related]
14. Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence. Vaddepally RK; Kharel P; Pandey R; Garje R; Chandra AB Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32245016 [TBL] [Abstract][Full Text] [Related]
15. Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma. Ivashko IN; Kolesar JM Am J Health Syst Pharm; 2016 Feb; 73(4):193-201. PubMed ID: 26843495 [TBL] [Abstract][Full Text] [Related]
16. Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells. Gibbons Johnson RM; Dong H Front Immunol; 2017; 8():961. PubMed ID: 28848559 [TBL] [Abstract][Full Text] [Related]
17. Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma. Kähler KC; Hassel JC; Heinzerling L; Loquai C; Mössner R; Ugurel S; Zimmer L; Gutzmer R; J Dtsch Dermatol Ges; 2016 Jul; 14(7):662-81. PubMed ID: 27373241 [TBL] [Abstract][Full Text] [Related]
18. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition. Jiang X; Zhou J; Giobbie-Hurder A; Wargo J; Hodi FS Clin Cancer Res; 2013 Feb; 19(3):598-609. PubMed ID: 23095323 [TBL] [Abstract][Full Text] [Related]
19. PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer? Tanvetyanon T; Gray JE; Antonia SJ Expert Opin Biol Ther; 2017 Mar; 17(3):305-312. PubMed ID: 28064556 [TBL] [Abstract][Full Text] [Related]
20. Aberrant apoptotic machinery confers melanoma dual resistance to BRAF(V600E) inhibitor and immune effector cells: immunosensitization by a histone deacetylase inhibitor. Jazirehi AR; Nazarian R; Torres-Collado AX; Economou JS Am J Clin Exp Immunol; 2014; 3(1):43-56. PubMed ID: 24660121 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]